Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

NCT03531905 PHASE2 COMPLETED Results posted

12 week study to assess the LDL-C lowering efficacy, other lipid and glycemic measures, and safety of bempedoic acid/ezetimibe FDC compared to ezetimibe and placebo in patients with type 2 diabetes (T2D) and elevated LDL-C

Details

Lead sponsor	Esperion Therapeutics, Inc.
Phase	PHASE2
Status	COMPLETED
Enrolment	242
Start date	Wed May 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Diabetes
• Diabetes Mellitus, Type 2
• Cholesterolemia

Interventions

• Bempedoic acid + Ezetimibe FDC Oral Tablet
• Ezetimibe 10 mg Oral Tablet
• Placebo Oral Tablet
• Placebo oral capsule

Countries

United States